MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
uniQure
QURE
|
+$20.3M |
| 2 |
Insmed
INSM
|
+$7.93M |
| 3 |
Verve Therapeutics
VERV
|
+$4.58M |
| 4 |
Intellia Therapeutics
NTLA
|
+$3.84M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$3.51M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merus
MRUS
|
+$18.4M |
| 2 |
Cytokinetics
CYTK
|
+$9.36M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$7.63M |
| 4 |
Y-mAbs Therapeutics
YMAB
|
+$6.4M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$2.99M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$667M
| $80.7M | 20.93% |
7,648,268
| – | – |
2021 Q1
7 quarters
|
|
2
DELISTED
iTeos Therapeutics
ITOS
| $34.1M | 8.85% |
1,745,943
| – | – |
2020 Q3
9 quarters
|
|
3
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $31.7M | 8.22% |
1,286,435
+6,440
| +0.5% | +$189K |
2022 Q2
2 quarters
|
|
4
DELISTED
Repare Therapeutics
RPTX
| $24.1M | 6.26% |
1,639,849
| – | – |
2020 Q2
10 quarters
|
|
|
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $22.7M | 5.89% |
1,059,688
+9,688
| +0.9% | +$207K |
2022 Q3
1 quarter
|
|
|
6
uniQure
QURE
$1.67B
| $21.3M | 5.53% |
+939,966
| New | +$20.3M |
2022 Q4
0 quarters
|
|
7
Geron
GERN
$623M
| $20.5M | 5.32% |
8,466,981
+44,399
| +0.5% | +$99.5K |
2021 Q3
5 quarters
|
|
|
8
Intellia Therapeutics
NTLA
$1.36B
| $15.9M | 4.12% |
455,238
+80,829
| +22% | +$3.84M |
2021 Q3
5 quarters
|
|
|
9
DELISTED
Verve Therapeutics
VERV
| $15.6M | 4.06% |
808,661
+172,869
| +27% | +$4.58M |
2022 Q3
1 quarter
|
|
10
Regenxbio
RGNX
$505M
| $14.1M | 3.66% |
621,372
+2,289
| +0.4% | +$51.7K |
2022 Q3
1 quarter
|
|
|
11
Iovance Biotherapeutics
IOVA
$3.59B
| $13.7M | 3.56% |
2,149,550
+449,550
| +26% | +$3.51M |
2022 Q2
2 quarters
|
|
|
PRVB
12
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $9.5M | 2.46% |
898,483
+158,139
| +21% | +$1.28M |
2022 Q2
2 quarters
|
|
|
13
Insmed
INSM
$26.6B
| $8.2M | 2.13% |
+410,463
| New | +$7.93M |
2022 Q4
0 quarters
|
|
14
Madrigal Pharmaceuticals
MDGL
$9.9B
| $7.77M | 2.02% |
26,773
-17,974
| -40% | -$1.76M |
2022 Q2
2 quarters
|
|
15
Harmony Biosciences
HRMY
$1.98B
| $7.68M | 1.99% |
139,377
+2,597
| +2% | +$143K |
2021 Q3
5 quarters
|
|
|
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $7.38M | 1.91% |
194,181
+15,123
| +8% | +$520K |
2022 Q1
3 quarters
|
|
17
DELISTED
Crinetics Pharmaceuticals
CRNX
| $6.8M | 1.76% |
371,639
+6,929
| +2% | +$122K |
2021 Q3
5 quarters
|
|
18
Travere Therapeutics
TVTX
$4.86B
| $5.92M | 1.54% |
281,711
+5,251
| +2% | +$111K |
2021 Q3
5 quarters
|
|
19
Werewolf Therapeutics
HOWL
$47.6M
| $4.9M | 1.27% |
2,388,011
| – | – |
2021 Q2
6 quarters
|
|
20
DELISTED
Amicus Therapeutics
FOLD
| $4.89M | 1.27% |
400,410
+7,464
| +2% | +$84K |
2021 Q3
5 quarters
|
|
21
Axsome Therapeutics
AXSM
$7.45B
| $4.01M | 1.04% |
+51,975
| New | +$3.11M |
2022 Q4
0 quarters
|
|
22
Arcutis Biotherapeutics
ARQT
$3.57B
| $3.88M | 1.01% |
262,069
+4,884
| +2% | +$85.3K |
2022 Q1
3 quarters
|
|
23
Revolution Medicines
RVMD
$37.3B
| $3.55M | 0.92% |
149,043
+3,002
| +2% | +$63.8K |
2021 Q3
5 quarters
|
|
24
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $3.53M | 0.92% |
650,000
-206,798
| -24% | -$1.73M |
2019 Q4
12 quarters
|
|
|
TCRR
25
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $3.37M | 0.87% |
3,370,982
| – | – |
2019 Q4
12 quarters
|
|
Similar funds
MPM BioImpact's Q4 2022 Portfolio in Review
As of Q4 2022, MPM BioImpact held 43 positions worth $385M, down 8.7% from $422M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
MPM BioImpact's Q4 2022 filing shows 5 new, 16 increased, 4 reduced and 10 closed positions. Its largest new stake was uniQure: 939,966 shares worth $21.3M. The largest sale was Merus, an estimated $18.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- MPM BioImpact's largest Q4 2022 buy was uniQure: 939,966 shares worth $21.3M.
- MPM BioImpact added most to Verve Therapeutics in Q4 2022, an estimated $4.58M increase.
- MPM BioImpact's biggest Q4 2022 reduction was Madrigal Pharmaceuticals, cutting an estimated $1.76M.
- MPM BioImpact fully exited Merus in Q4 2022, selling an estimated $18.4M.
- MPM BioImpact's ten largest holdings make up 73% of its $385M portfolio in Q4 2022.
- MPM BioImpact opened 5 new positions and closed 10 in Q4 2022.
- MPM BioImpact's portfolio value fell 8.7% quarter-over-quarter to $385M.
Based on MPM BioImpact's 13F filing for Q4 2022, filed 14 Feb 2023.